RetaCalc
Protocol library
SingleApprovedRegulatory LabelSourced

Tesamorelin

A growth hormone-releasing factor analogue with an authorised US medicine for a narrow indication. The label does not support general weight-loss or anti-ageing use.

Evidence context, not a personal protocol

Quantities below reproduce study or label context. They do not assess suitability, product equivalence or individual risk.

Regimens studied

Adults with the authorised Egrifta SV indication

The current label specifies a formulation-specific once-daily subcutaneous dose

Exact preparation and administration must come from the current regulated product label.

View source

Evidence summary

Tesamorelin has a regulated product for reducing excess abdominal fat in a defined patient population. The label states important limitations and formulation-specific instructions.

Scope

Evidence for the authorised indication must not be generalised to bodybuilding, anti-ageing or non-prescription research products.

Warnings and contraindications

The authorised indication is narrow and requires clinical diagnosis and monitoring.
Different tesamorelin formulations are not interchangeable on a milligram-for-milligram basis.

Contraindications reported by the source

Pregnancy
Active malignancy
Disruption of the hypothalamic-pituitary axis